Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586909 · ClinicalTrials.gov registry record · Phase 3
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
A Phase 3 study, sponsored by Axovant Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,099
- Enrollment target
NCT02586909: Clinical Trial Phase 3 study, sponsored by Axovant Sciences.
NCT02586909 is a Phase 3 study that was terminated before completion, run by Axovant Sciences. The registered enrollment target is 1,099 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02586909, a Phase 3 study, was terminated before completion, sponsored by Axovant Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,099 participants
- Enrollment target
Study Summary
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).
Primary Outcome
The primary outcome measure is to study the safety of Intepridine (RVT-101) by determining the incidence of AEs, changes in physical examinations, vital signs measurements, ECGs and clinical laboratory assessments
Interventions
- DRUG RVT-101 35 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,099 participants |
| Start Date | 2016-04-26 |
| Est. Completion | 2018-03-12 |
| Phase | Phase 3 |
Why NCT02586909 stopped before completion
NCT02586909 is an interventional study that assigns participants to a tested intervention. Its 1,099 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 1 intervention - of which RVT-101 35 mg tablets is the first listed.
NCT02586909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02586909 about?
NCT02586909 is a clinical study titled "12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension". This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).
What is the current status of trial NCT02586909?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,099 participants. The study started on 2016-04-26. Estimated completion is 2018-03-12.
What interventions are being tested in trial NCT02586909?
The interventions under investigation include: RVT-101 35 mg tablets (DRUG).
Who is sponsoring clinical trial NCT02586909?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02586909's enrollment target sits among peer trials
1,099 265th of 2000 higher than 1,736 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI